Optimization of experimental conditions for functional in vitro characterization of humanized antibodies specific for Staphylococcal Enterotoxin B

Por MacIntyre, Jennifer L, Varshney, Avanish K, Wang, Xiaobo, Gatto, Scott, Friedman, Clarence, Liu, Yan, Kerns, Kelvin, Kovalenko, Oleg, Adkins, Karissa, Zollner, Richard, Fries, Bettina C., Byrne, Fergus R
Publicado no Int Immunopharmacol (2015)

Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing

Por Weng, Yan, Ishino, Tetsuya, Sievers, Annette, Talukdar, Saswata, Chabot, Jeffrey R., Tam, Amy, Duan, Weili, Kerns, Kelvin, Sousa, Eric, He, Tao, Logan, Alison, Lee, Darwin, Li, Dongmei, Zhou, Yingjiang, Bernardo, Barbara, Joyce, Alison, Kavosi, Mania, O’Hara, Denise M., Clark, Tracey, Guo, Jie, Giragossian, Craig, Stahl, Mark, Calle, Roberto A., Kriz, Ron, Somers, Will, Lin, Laura
Publicado no Sci Rep (2018)

Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer

Por Root, Adam R., Cao, Wei, Li, Bilian, LaPan, Peter, Meade, Caryl, Sanford, Jocelyn, Jin, Macy, O’Sullivan, Cliona, Cummins, Emma, Lambert, Matthew, Sheehan, Alfredo D., Ma, Weijun, Gatto, Scott, Kerns, Kelvin, Lam, Khetemenee, D’Antona, Aaron M., Zhu, Lily, Brady, William A., Benard, Susan, King, Amy, He, Tao, Racie, Lisa, Arai, Maya, Barrett, Dianah, Stochaj, Wayne, LaVallie, Edward R., Apgar, James R., Svenson, Kristine, Mosyak, Lidia, Yang, Yinhua, Chichili, Gurunadh R., Liu, Liqin, Li, Hua, Burke, Steve, Johnson, Syd, Alderson, Ralph, Finlay, William J. J., Lin, Laura, Olland, Stéphane, Somers, William, Bonvini, Ezio, Gerber, Hans-Peter, May, Chad, Moore, Paul A., Tchistiakova, Lioudmila, Bloom, Laird
Publicado no Antibodies (Basel) (2016)